Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Disappearance of Serum Methylated p16 Indicates Longer Survival in Patients with Gastric Cancer

  • Lim, Han-Ki (Department of Surgery, Chung-Ang University College of Medicine) ;
  • Park, Joong-Min (Department of Surgery, Chung-Ang University College of Medicine) ;
  • Chi, Kyong-Choun (Department of Surgery, Chung-Ang University College of Medicine) ;
  • Lee, Eun-Ju (Department of Obstetrics and Gynecology, Chung-Ang University College of Medicine) ;
  • Jeong, Eun-Mi (Department of Obstetrics and Gynecology, Chung-Ang University College of Medicine)
  • Received : 2013.07.15
  • Accepted : 2013.09.09
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to assess clinical correlations with postoperative alteration of p16 DNA methylation, and to clarify whether postoperative changes in the serum DNA methylation status of p16 could be used as a reliable prognostic factor for gastric cancer. Materials and Methods: Fifty-three consecutive gastric adenocarcinoma patients who underwent gastric resection (Chung-Ang University Hospital, Seoul, Korea) were included. DNA methylation of p16 was evaluated by methylation-specific polymerase chain reaction using serum DNA preoperatively and at the 10th postoperative day. The correlation between changes in methylation status and patients' prognosis was analyzed. Results: p16 was methylated in 79.2% of preoperative serum DNA and in 54.7% of postoperative serum DNA, respectively. Methylation in p16 disappeared more frequently in patients who underwent standard D2 lymphadenectomy compared to those who underwent modified D1+ lymphadenectomy (P=0.016). Whereas methylation of preoperative serum DNA was not correlated with survival, patients with postoperative disappearance of p16 methylation showed longer survival than those without postoperative disappearance of p16 methylation in the patients who had gastric cancer with lymph node metastasis (P=0.042). Conclusions: Postoperative disappearance of p16 methylation could be an available prognostic factor for node-positive gastric cancer.

Keywords

References

  1. Desai AM, Pareek M, Nightingale PG, Fielding JW. Improving outcomes in gastric cancer over 20 years. Gastric Cancer 2004;7:196-201. https://doi.org/10.1007/s10120-004-0289-0
  2. Park JM, Ryu WS, Kim JH, Park SS, Kim SJ, Kim CS, et al. Prognostic factors for advanced gastric cancer: stage-stratified analysis of patients who underwent curative resection. Cancer Res Treat 2006;38:13-18. https://doi.org/10.4143/crt.2006.38.1.13
  3. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449-461. https://doi.org/10.1097/00000658-199810000-00002
  4. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463. https://doi.org/10.1038/nature02625
  5. Ikoma H, Ichikawa D, Daito I, Nobuyuki T, Koike H, Okamoto K, et al. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology 2007;54:946-950.
  6. Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001;61:2847-2851.
  7. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999;59:5438- 5442.
  8. Oue N, Sentani K, Yokozaki H, Kitadai Y, Ito R, Yasui W. Promoter methylation status of the DNA repair genes hMLH1 and MGMT in gastric carcinoma and metaplastic mucosa. Pathobiology 2001;69:143-149. https://doi.org/10.1159/000048769
  9. Lee JH, Park SJ, Abraham SC, Seo JS, Nam JH, Choi C, et al. Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 2004;23:4646-4654. https://doi.org/10.1038/sj.onc.1207588
  10. Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003;83:635-641. https://doi.org/10.1097/01.LAB.0000067481.08984.3F
  11. Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006;106:1250-1259. https://doi.org/10.1002/cncr.21754
  12. Goto T, Mizukami H, Shirahata A, Yokomizo K, Kitamura YH, Sakuraba K, et al. Methylation of the p16 gene is frequently detected in lymphatic-invasive gastric cancer. Anticancer Res 2010;30:2701-2703.
  13. Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, et al. Aberrant methylation of p16 predicts candidates for 5-fluorouracil- based adjuvant therapy in gastric cancer patients. J Gastroenterol 2007;42:866-873. https://doi.org/10.1007/s00535-007-2113-1
  14. Sobin LH, Gospodarowicz MK, Wittekind C, eds. International Union against Cancer. TNM Classification of Malignant Tumours. 7th ed. West Sussex, Hoboken: Blackwell Publisging Ltd., 2010.
  15. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-9826. https://doi.org/10.1073/pnas.93.18.9821
  16. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 2005;11:656-663.
  17. Shi J, Zhang G, Yao D, Liu W, Wang N, Ji M, et al. Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res 2012;2:116-129.
  18. Tsujie M, Yamamoto H, Tomita N, Sugita Y, Ohue M, Sakita I, et al. Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Oncology 2000;58:126-136. https://doi.org/10.1159/000012089
  19. Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D, et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998;58:1405-1407.
  20. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from nonsmall cell lung cancer patients. Cancer Res 1999;59:67-70.
  21. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59:71-73.
  22. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002;8:1761-1766.
  23. Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer 2005;92:2190-2194. https://doi.org/10.1038/sj.bjc.6602636

Cited by

  1. Association of DNA Methylation with Acute Mania and Inflammatory Markers vol.10, pp.7, 2013, https://doi.org/10.1371/journal.pone.0132001
  2. Challenges of deciphering gastric cancer heterogeneity vol.21, pp.37, 2015, https://doi.org/10.3748/wjg.v21.i37.10510
  3. Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma vol.23, pp.20, 2013, https://doi.org/10.3748/wjg.v23.i20.3721
  4. Effect of interventional embolotherapy on FHIT and p16 expression in hepatocellular carcinoma patients vol.17, pp.1, 2019, https://doi.org/10.3892/ol.2018.9648
  5. DNA hypomethylation promotes invasion and metastasis of gastric cancer cells by regulating the binding of SP1 to the CDCA3 promoter vol.121, pp.1, 2020, https://doi.org/10.1002/jcb.28993